Drug Profile


Alternative Names: Bispec; Solifenacin succinate; Vesicare; Vesicare OD; VESIcare®; YM 67905; YM 905

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Antispasmodics; Esters; Isoquinolines; Quinuclidines; Small molecules; Urologics
  • Mechanism of Action Muscarinic M1 receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Overactive bladder
  • No development reported Irritable bowel syndrome

Most Recent Events

  • 30 Apr 2016 Astellas Pharma completes a phase III trial for paediatric Overactive bladder in USA, Belgium, Brazil, Denmark, Hungary, South Korea, Mexico, Philippines, Poland and Turkey (NCT01565694)
  • 01 Dec 2015 Astellas Pharma completes the Marmoset trial in overactive bladder in USA, Belgium, South Korea, Philippines, Poland, United Kingdom, Netherlands and Denmark (NCT01981954/ EudraCT2012-003178-22)
  • 01 Sep 2015 Preregistration for Overactive bladder (In adolescents, In children) in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top